A weighted cardiometabolic disease staging risk score can be used to quantify race- and sex-specific type 2 diabetes risk in a large, diverse population, according to study results presented at the American Association of Clinical Endocrinologists 28th Annual Scientific & Clinical Congress, held April 24 to 28 in Los Angeles, California.

For this study, investigators sought to predict risk for diabetes within nationally sampled data from white and black American adults age ≥45 years using a cardiometabolic risk score. Patients from the REGARDS study (REasons for Geographic and Racial Differences in Stroke), a population-based cohort of 12,123 black and white men and women, were followed from 2013 to 2016 and assessed using a series of logistic regressions that accounted for waist circumference, blood pressure, blood glucose, high-density lipoprotein cholesterol, age, triglycerides, and cholesterol. An external validation was performed using 9712 participants from Atherosclerotic Risk in Communities during 1987 to 1989.

Related Articles

There were 1614 incident cases of diabetes in the REGARDS cohort, and researchers discovered that cardiometabolic risks differed more by race than by sex (P =.0001). C-statistics ranged from 0.72 (95% CI, 0.72-0.75) for black men to 0.79 (95% CI, 0.79-0.81) for white women. Externally validated models performed equally well or better than the original model; C-statistics ranged from 0.75 (95% CI, 0.75-0.80) for black men to 0.83 (95% CI, 0.83-0.86) for white women.

The investigators concluded that this weighted cardiometabolic disease staging score “can be used for [type 2 diabetes] prevention efforts by allowing clinicians to target [high-risk] individuals in a manner that could be used to optimize outcomes.”

Follow @EndoAdvisor

Reference

Wilkinson L, Mehta T, Guo F, Garvey WT. Cardiometabolic disease staging predicts incident diabetes in a large and diverse population: racial and gender differences. Presented at: American Association of Clinical Endocrinologists 28th Annual Scientific & Clinical Congress; April 24-28, 2019; Los Angeles, CA.